StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a report issued on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.
Aptevo Therapeutics Stock Performance
Shares of NASDAQ:APVO opened at $0.31 on Friday. Aptevo Therapeutics has a 52-week low of $0.24 and a 52-week high of $32.93. The business has a 50-day moving average price of $1.06 and a 200-day moving average price of $60.38.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last posted its earnings results on Thursday, May 15th. The biotechnology company reported ($4.39) earnings per share for the quarter, missing the consensus estimate of ($4.21) by ($0.18). Analysts forecast that Aptevo Therapeutics will post -15.84 EPS for the current year.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Recommended Stories
- Five stocks we like better than Aptevo Therapeutics
- Using the MarketBeat Dividend Tax Calculator
- Top 5 Stocks Hedge Funds Are Buying Right Now
- How to trade penny stocks: A step-by-step guide
- Viking Holdings Posts Strong Q1, Eyes Growth Ahead
- 5 Top Rated Dividend Stocks to Consider
- 2 Reasons Netflix’s 40% Rally Is Far From Over
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
